David Zaccardelli, Verona Pharma CEO

Verona says sec­ond PhI­II for COPD drug hits the mark, plans 2023 NDA fil­ing

UK-based biotech Verona Phar­ma said Tues­day morn­ing that its drug, en­sifen­trine, passed its sec­ond late-stage tri­al for the com­mon lung dis­ease COPD.

In Au­gust, Verona re­port­ed the drug suc­ceed­ed in the first of its two Phase III tri­als. Now, Verona will pack­age to­geth­er the new tri­al da­ta in its ap­proval fil­ing to the FDA, which the biotech said will come in the first half of next year.

Verona’s stock $VR­NA opened around 30% above its last close, jump­ing from un­der $14 to near­ly $17.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.